Skip to main content

Respiratory Tract Infections clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for
  • Cell therapy to Treat Patients with COVID-19

    open to eligible people ages 18 years and up

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    Sacramento, California and other locations

  • Experimental HostDx Sepsis for Emergency Department Patients With Suspected Infections and/or Sepsis

    open to eligible people ages 18 years and up

    This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin & soft tissue infections; or suspected sepsis of any cause.

    Sacramento, California and other locations

Last updated: